tranexamic acid has been researched along with Osteoarthritis, Knee in 72 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Osteoarthritis, Knee: Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of this study was to compare the effects of intra-articular (IA) administration of tranexamic acid (TXA), an anti-fibrinolytic commonly used in TKA, and ALM chondroprotective solution on postoperative inflammation and joint tissue healing in a rat model of knee implant surgery." | 8.02 | Comparison of intra-articular administration of adenosine, lidocaine and magnesium solution and tranexamic acid for alleviating postoperative inflammation and joint fibrosis in an experimental model of knee arthroplasty. ( Biros, E; Dlaska, C; Dobson, GP; Hazratwala, K; Letson, HL; McEwen, P; Morris, JL; Wilkinson, M, 2021) |
| "The aim of this study was to evaluate the effects of a high initial-dose (60 mg/kg) intravenous tranexamic acid (IV-TXA) on fibrinolysis and inflammation after total knee arthroplasty (TKA)." | 5.34 | The antifibrinolytic and anti-inflammatory effects of a high initial-dose tranexamic acid in total knee arthroplasty: a randomized controlled trial. ( Huang, Q; Huang, W; Lei, YT; Pei, FX; Xie, JW, 2020) |
| " The purpose of this study was to compare the effects of intra-articular (IA) administration of tranexamic acid (TXA), an anti-fibrinolytic commonly used in TKA, and ALM chondroprotective solution on postoperative inflammation and joint tissue healing in a rat model of knee implant surgery." | 4.02 | Comparison of intra-articular administration of adenosine, lidocaine and magnesium solution and tranexamic acid for alleviating postoperative inflammation and joint fibrosis in an experimental model of knee arthroplasty. ( Biros, E; Dlaska, C; Dobson, GP; Hazratwala, K; Letson, HL; McEwen, P; Morris, JL; Wilkinson, M, 2021) |
| "Secondary outcome criteria were postoperative pain, intraarticular effusion (measured by ultrasound), range of motion (ROM) at discharge, peri- and postoperative complications and the KOOS PS (pre- and postoperatively at 1 year follow up)." | 3.11 | Use of tranexamic acid in medial open wedge high tibial osteotomy. ( Bentzin, M; Bierke, S; Häner, M; Park, HU; Petersen, W, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug." | 2.90 | Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels. ( Baaklini, LR; Cross, JR; Fields, KG; Jules-Elysee, KM; Mayman, DJ; McLawhorn, AS; Pickard, AJ; Qin, W; Sculco, TP; Su, EP; Tseng, A, 2019) |
| "To compare postoperative blood loss after intravenous and intraarticular tranexamic acid injection in patients of bilateral total knee arthroplasty." | 2.87 | Blood loss after intraarticular and intravenous tranexamic acid in total knee arthroplasty. ( Ahmad, S; Ahmed, A; Ahmed, S; Aziz, A; Javed, S, 2018) |
| "The combined (IV (intravenous) + topical) use of tranexamic acid (TXA) has been shown to be a safe method and more effective than single (IV or topical) application." | 2.84 | The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty. ( Akkaya, M; Basaran, SH; Bozkurt, M; Cankaya, D; Dasar, U; Satilmis, AB, 2017) |
| "TXA treatment without drainage during TKA reduces the amount of blood transfusions required without increasing the rate of adverse events." | 2.80 | Safety and efficacy of intra-articular tranexamic acid injection without drainage on blood loss in total knee arthroplasty: A randomized clinical trial. ( Cao, JG; Li, ZJ; Liu, J; Sun, ZH; Wang, CG, 2015) |
| "Several methods reportedly reduce postoperative blood loss and avoid homologous blood transfusion with traditional TKA approaches, but it is unclear these reductions apply to a minimally invasive technique." | 2.76 | Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial. ( Charoencholvanich, K; Siriwattanasakul, P, 2011) |
| " In Group A, 1 g of tranexamic acid dissolved in 250 ml of normal saline was intravenously infused before deflation of the tourniquet; another intravenous administration of the same drug of the same dosage was given 3 hours later." | 2.73 | [Clinical comparative studies on effect of tranexamic acid on blood loss associated with total knee arthroplasty]. ( Gao, Z; Yu, J; Zhang, F, 2007) |
| "Tranexamic acid (TXA) has been shown to be effective in patients with total knee arthroplasty (TKA) in clinical studies with no consensus with regard to the most appropriate route of administration." | 2.58 | Tranexamic Acid in Total Knee Arthroplasty: Mixed Treatment Comparisons and Recursive Cumulative Meta-Analysis of Randomized, Controlled Trials and Cohort Studies. ( Sivaramakrishnan, G; Sridharan, K, 2018) |
| "The present meta-analysis indicated that intra-articular injection of TXA in patients undergoing TKA may reduce total blood loss and the need for blood transfusions, particularly when a high dosage of TXA is used (≥30 mg/ml), without any increase in the risk of post-operative DVT." | 2.50 | Reduced blood loss after intra-articular tranexamic acid injection during total knee arthroplasty: a meta-analysis of the literature. ( Wei, C; Yan, G; Ying-Ze, Z; Yuejv, L; Zhao-Yu, C, 2014) |
| "To investigate whether intravenous combined with topical administration of tranexamic acid (TXA) is superior to intravenous administration alone in terms of blood loss, incision complications, functional recovery, and pain relief in high tibial osteotomy (HTO)." | 1.56 | Intravenous Combined with Topical Tranexamic Acid Administration Has No Additional Benefits Compared with Intravenous Administration Alone in High Tibial Osteotomy: A Retrospective Case-Control Study. ( Guo, X; Li, S; Liu, P; Lu, Q; Luo, D; Miao, Z; Zhang, M, 2020) |
| " Previous studies have established the efficacy of TXA in TKA, however here are limited direct comparison studies available and the dosing regimens vary." | 1.56 | Higher doses of topical tranexamic acid safely improves immediate functional outcomes and reduces transfusion requirement in total knee arthroplasty. ( Tan, C; Wang, L; Wu, C, 2020) |
| "Thirty-four patients with haemophilia A undergoing 24 TKA and 18 THA were evaluated in this retrospective study (No." | 1.51 | Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia. ( Huang, Q; Huang, ZY; Ma, J; Pei, FX; Shen, B; Zeng, HJ; Zhou, ZK, 2019) |
| "The intravenous TXA would reduce postoperative blood loss and transfusion requirements without increasing thromboembolic complications in open-wedge HTO." | 1.48 | Tranexamic acid is effective for blood management in open-wedge high tibial osteotomy. ( Bae, SH; Kim, GB; Kim, HJ; Kim, KI, 2018) |
| "Male appeared to suffer more surgical blood loss than female." | 1.48 | Blood loss of total knee arthroplasty in osteoarthritis: an analysis of influential factors. ( Hu, Y; Li, Q; Shi, ZJ; Torsha, TT; Wei, BG; Xiao, J; Zhang, XS, 2018) |
| "This study aimed to compare the efficacy of intravenous administration of tranexamic acid for reducing blood loss in total knee arthroplasty at different dosage time." | 1.46 | The Efficacy Comparison of Tranexamic Acid for Reducing Blood Loss in Total Knee Arthroplasty at Different Dosage Time. ( Cai, M; Gong, J; Nie, X; Sun, Q; Yu, X, 2017) |
| "There were no deep venous thrombosis or thromboembolic complications in any group." | 1.43 | A comparative, retrospective study of peri-articular and intra-articular injection of tranexamic acid for the management of postoperative blood loss after total knee arthroplasty. ( Dai, K; Mao, Z; Wang, Y; Yan, M; Yue, B, 2016) |
| " However, few studies have reported the optimum timing and dosage for administration of TXA." | 1.39 | Repeat-dose intravenous tranexamic acid further decreases blood loss in total knee arthroplasty. ( Hamada, M; Hideki, Y; Iwai, T; Sugamoto, K; Tomita, T; Tsuji, S, 2013) |
| "Tranexamic acid (TA) is an inexpensive antifibrinolytic agent that is little used in orthopaedic surgery due to the absence of standardised optimal administration regimens." | 1.38 | Tranexamic acid reduces blood loss and financial cost in primary total hip and knee replacement surgery. ( Argenson, JN; Hémon, Y; Irisson, E; Kerbaul, F; Parratte, S; Pauly, V, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (2.78) | 29.6817 |
| 2010's | 57 (79.17) | 24.3611 |
| 2020's | 13 (18.06) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, MR | 1 |
| Jun, CM | 1 |
| Song, SK | 1 |
| Choi, WK | 1 |
| Petersen, W | 1 |
| Bentzin, M | 1 |
| Bierke, S | 1 |
| Park, HU | 1 |
| Häner, M | 1 |
| Wang, L | 4 |
| Zhang, Z | 1 |
| Xiong, W | 1 |
| Fang, Q | 1 |
| Tang, Y | 1 |
| Wang, G | 1 |
| Morris, JL | 1 |
| Letson, HL | 1 |
| McEwen, P | 1 |
| Biros, E | 1 |
| Dlaska, C | 1 |
| Hazratwala, K | 1 |
| Wilkinson, M | 1 |
| Dobson, GP | 1 |
| Moorthy, V | 3 |
| Chen, JY | 5 |
| Liow, MHL | 3 |
| Pang, HN | 4 |
| Tay, DK | 5 |
| Chia, SL | 5 |
| Lo, NN | 5 |
| Yeo, SJ | 5 |
| Iseki, T | 2 |
| Kanto, R | 1 |
| Onishi, S | 1 |
| Yoshiya, S | 1 |
| Tachibana, T | 1 |
| Nakayama, H | 1 |
| Huang, ZY | 1 |
| Huang, Q | 3 |
| Zeng, HJ | 1 |
| Ma, J | 1 |
| Shen, B | 2 |
| Zhou, ZK | 2 |
| Pei, FX | 3 |
| Lostak, J | 1 |
| Gallo, J | 1 |
| Slavik, L | 1 |
| Zapletalova, J | 1 |
| Balaz, L | 1 |
| Tsukada, S | 1 |
| Kurosaka, K | 1 |
| Nishino, M | 1 |
| Maeda, T | 1 |
| Yonekawa, Y | 1 |
| Hirasawa, N | 1 |
| Wang, HY | 1 |
| Luo, ZY | 1 |
| Wang, D | 1 |
| Tang, X | 1 |
| Jules-Elysee, KM | 1 |
| Tseng, A | 1 |
| Sculco, TP | 1 |
| Baaklini, LR | 1 |
| McLawhorn, AS | 1 |
| Pickard, AJ | 1 |
| Qin, W | 1 |
| Cross, JR | 1 |
| Su, EP | 1 |
| Fields, KG | 1 |
| Mayman, DJ | 1 |
| Lei, YT | 1 |
| Xie, JW | 1 |
| Huang, W | 1 |
| Li, S | 1 |
| Lu, Q | 1 |
| Guo, X | 1 |
| Zhang, M | 1 |
| Miao, Z | 1 |
| Luo, D | 1 |
| Liu, P | 1 |
| Tandogan, RN | 1 |
| Polat, M | 1 |
| Beyzadeoglu, T | 1 |
| Karabulut, E | 1 |
| Yildirim, K | 1 |
| Kayaalp, A | 1 |
| Şahin, İG | 1 |
| Akalin, Y | 1 |
| Çevik, N | 1 |
| Otuzbir, A | 1 |
| Özkan, Y | 1 |
| Öztürk, A | 1 |
| Wu, C | 1 |
| Tan, C | 1 |
| Li, Z | 1 |
| Wang, Y | 2 |
| Cao, G | 2 |
| An, S | 1 |
| Feng, M | 1 |
| Wang, X | 1 |
| Yang, G | 1 |
| Gao, G | 1 |
| Wang, S | 1 |
| Jiao, X | 1 |
| Ding, L | 1 |
| Zhang, S | 2 |
| Wang, F | 1 |
| Wang, C | 2 |
| Chu, P | 1 |
| Shi, L | 2 |
| Xue, Q | 2 |
| Liu, W | 1 |
| Yang, C | 1 |
| Huang, X | 1 |
| Liu, R | 1 |
| Eachempati, KK | 1 |
| Gurava Reddy, AV | 1 |
| Apsingi, S | 1 |
| Sankineani, SR | 1 |
| Shaheed, J | 1 |
| Dannana, C | 1 |
| Sridharan, K | 1 |
| Sivaramakrishnan, G | 1 |
| Lacko, M | 1 |
| Cellar, R | 1 |
| Schreierova, D | 1 |
| Vasko, G | 1 |
| Arora, M | 1 |
| Singh, S | 1 |
| Gupta, V | 1 |
| Dongre, A | 1 |
| Shetty, V | 1 |
| Kim, KI | 2 |
| Kim, HJ | 1 |
| Kim, GB | 1 |
| Bae, SH | 1 |
| Lévy, Y | 1 |
| Azar, M | 1 |
| Tran, L | 1 |
| Boileau, P | 1 |
| Bronsard, N | 1 |
| Trojani, C | 1 |
| Ahmed, S | 1 |
| Ahmed, A | 1 |
| Ahmad, S | 1 |
| Javed, S | 1 |
| Aziz, A | 1 |
| Hu, Y | 1 |
| Li, Q | 1 |
| Wei, BG | 1 |
| Zhang, XS | 1 |
| Torsha, TT | 1 |
| Xiao, J | 1 |
| Shi, ZJ | 1 |
| Tzatzairis, T | 1 |
| Drosos, GI | 2 |
| Vogiatzaki, T | 1 |
| Tilkeridis, K | 1 |
| Ververidis, A | 1 |
| Kazakos, K | 1 |
| Laoruengthana, A | 1 |
| Rattanaprichavej, P | 1 |
| Chaibhuddanugul, N | 1 |
| Varakornpipat, P | 1 |
| Galassi, M | 1 |
| Pongpirul, K | 1 |
| Chen, G | 1 |
| Huang, Z | 2 |
| Alexander, PG | 1 |
| Lin, H | 1 |
| Xu, H | 1 |
| Zhou, Z | 2 |
| Pei, F | 2 |
| Tille, E | 1 |
| Mysliwietz, J | 1 |
| Beyer, F | 1 |
| Postler, A | 1 |
| Lützner, J | 1 |
| Forget, P | 1 |
| Grosu, I | 1 |
| Thienpont, E | 1 |
| Iwai, T | 2 |
| Tsuji, S | 2 |
| Antinolfi, P | 1 |
| Innocenti, B | 1 |
| Caraffa, A | 1 |
| Peretti, G | 1 |
| Cerulli, G | 1 |
| Dahuja, A | 1 |
| Dahuja, G | 1 |
| Jaswal, V | 1 |
| Sandhu, K | 1 |
| Zhao-Yu, C | 1 |
| Yan, G | 1 |
| Wei, C | 1 |
| Yuejv, L | 1 |
| Ying-Ze, Z | 1 |
| Rikhraj, IS | 1 |
| Chin, PL | 2 |
| Panni, AS | 1 |
| Cerciello, S | 1 |
| Vasso, M | 1 |
| Del Regno, C | 1 |
| Jang, B | 1 |
| Kao, M | 1 |
| Bohm, MT | 1 |
| Harris, IA | 1 |
| Chen, DB | 1 |
| MacDessi, SJ | 2 |
| Upadhyay, S | 1 |
| Raza, HK | 1 |
| Kaplunov, OA | 1 |
| Mikhin, IV | 1 |
| Biriukov, SN | 1 |
| Karaaslan, F | 1 |
| Karaoğlu, S | 1 |
| Mermerkaya, MU | 1 |
| Baktir, A | 1 |
| Hourlier, H | 1 |
| Reina, N | 1 |
| Fennema, P | 1 |
| Wang, CG | 1 |
| Sun, ZH | 1 |
| Liu, J | 1 |
| Cao, JG | 1 |
| Li, ZJ | 1 |
| Digas, G | 1 |
| Koutsogiannis, I | 1 |
| Meletiadis, G | 1 |
| Antonopoulou, E | 1 |
| Karamoulas, V | 1 |
| Bikos, Ch | 1 |
| Zhang, W | 1 |
| Li, W | 1 |
| Bai, G | 1 |
| Zhang, C | 1 |
| Lin, J | 1 |
| Moo, IH | 1 |
| Aggarwal, AK | 1 |
| Singh, N | 1 |
| Sudesh, P | 1 |
| Rodriguez-Merchan, EC | 1 |
| Ortega-Andreu, M | 1 |
| Padilla-Eguiluz, NG | 1 |
| Gomez-Cardero, P | 1 |
| Martinez-Lloreda, Á | 1 |
| Gomez-Barrena, E | 1 |
| Uğurlu, M | 1 |
| Aksekili, MA | 1 |
| Çağlar, C | 1 |
| Yüksel, K | 1 |
| Şahin, E | 1 |
| Akyol, M | 1 |
| Nielsen, CS | 1 |
| Jans, Ø | 1 |
| Ørsnes, T | 1 |
| Foss, NB | 1 |
| Troelsen, A | 1 |
| Husted, H | 1 |
| Tzatzairis, TK | 1 |
| Kotsios, SE | 1 |
| Ververidis, AN | 1 |
| Vogiatzaki, TD | 1 |
| Kazakos, KI | 1 |
| Sun, Q | 1 |
| Yu, X | 1 |
| Nie, X | 1 |
| Gong, J | 1 |
| Cai, M | 1 |
| Pinsornsak, P | 1 |
| Rojanavijitkul, S | 1 |
| Chumchuen, S | 1 |
| Guzel, Y | 1 |
| Gurcan, OT | 1 |
| Golge, UH | 1 |
| Dulgeroglu, TC | 1 |
| Metineren, H | 1 |
| Song, EK | 1 |
| Seon, JK | 1 |
| Prakash, J | 1 |
| Seol, YJ | 1 |
| Park, YJ | 1 |
| Jin, C | 1 |
| Spanyer, J | 1 |
| Patel, J | 1 |
| Emberton, E | 1 |
| Smith, LS | 1 |
| Malkani, AL | 1 |
| Mao, Z | 1 |
| Yue, B | 1 |
| Yan, M | 1 |
| Dai, K | 1 |
| Maniar, RN | 1 |
| Singhi, T | 1 |
| Patil, A | 1 |
| Kumar, G | 1 |
| Maniar, P | 1 |
| Singh, J | 1 |
| Cankaya, D | 1 |
| Dasar, U | 1 |
| Satilmis, AB | 1 |
| Basaran, SH | 1 |
| Akkaya, M | 1 |
| Bozkurt, M | 1 |
| Wu, Y | 1 |
| Yang, T | 1 |
| Zeng, Y | 1 |
| Li, C | 1 |
| Ishida, K | 1 |
| Tsumura, N | 1 |
| Kitagawa, A | 1 |
| Hamamura, S | 1 |
| Fukuda, K | 1 |
| Dogaki, Y | 1 |
| Kubo, S | 1 |
| Matsumoto, T | 1 |
| Matsushita, T | 1 |
| Chin, T | 1 |
| Iguchi, T | 1 |
| Kurosaka, M | 1 |
| Kuroda, R | 1 |
| Charoencholvanich, K | 1 |
| Siriwattanasakul, P | 1 |
| Sepah, YJ | 1 |
| Umer, M | 1 |
| Ahmad, T | 1 |
| Nasim, F | 1 |
| Chaudhry, MU | 1 |
| Umar, M | 1 |
| Roy, SP | 1 |
| Tanki, UF | 1 |
| Dutta, A | 1 |
| Jain, SK | 1 |
| Nagi, ON | 1 |
| Irisson, E | 1 |
| Hémon, Y | 1 |
| Pauly, V | 1 |
| Parratte, S | 1 |
| Argenson, JN | 1 |
| Kerbaul, F | 1 |
| Lee, SH | 1 |
| Cho, KY | 1 |
| Khurana, S | 1 |
| Tomita, T | 1 |
| Sugamoto, K | 1 |
| Hideki, Y | 1 |
| Hamada, M | 1 |
| Good, L | 1 |
| Peterson, E | 1 |
| Lisander, B | 1 |
| Zhang, F | 1 |
| Gao, Z | 1 |
| Yu, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Extended Postoperative Tranexamic Acid Use in Primary Total Knee Arthroplasty: A Prospective, Randomized Controlled Trial[NCT05099276] | Phase 4 | 46 participants (Actual) | Interventional | 2021-12-07 | Active, not recruiting | ||
| Prospective, Multicenter, Randomized, Parallel Groups Study Comparing the Safety and the Efficacy of the Administration of One Intra-articular Injection of 4.8 ml (HO-1) or Three Intra-articular Injections of 2.2 ml (HS-3) of Pandora Gel to One Intra-arti[NCT05978180] | 252 participants (Anticipated) | Interventional | 2023-10-18 | Recruiting | |||
| Prospective, Multicenter, Open Study Evaluating the Short-term Safety of Use of Pandora Administered in the Form of 1 Intra-articular Injection of Happyone or 3 Intra-articular Injections of Happysoft in Patients Suffering From Gonarthrosis[NCT05414617] | 20 participants (Actual) | Interventional | 2022-06-08 | Completed | |||
| Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage[NCT05554211] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-07-12 | Recruiting | ||
| Effect of no Drainage Tube on Blood Loss and Recovery After High Tibial Osteotomy[NCT03954860] | 80 participants (Actual) | Interventional | 2018-08-01 | Completed | |||
| Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty: A Randomized Controlled Trial[NCT02829346] | Phase 2 | 60 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Evaluation of Efficacy and Safety of Perioperative Tranexamic Acid During Primary Total Knee Arthroplasty: A Randomized, Clinical Trial[NCT05919615] | 100 participants (Actual) | Interventional | 2021-07-15 | Completed | |||
| Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients: A Randomized Controlled Study[NCT03109652] | Phase 4 | 144 participants (Anticipated) | Interventional | 2017-07-10 | Recruiting | ||
| The Comparative Efficacy of Peri-articular and Intraarticular Tranexamic Acid in Total Knee Arthroplasty: A Prospective, Double-Blind Randomized, Controlled Trial[NCT03074994] | Phase 2 | 108 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| Efficacy of Local Hemostatic Management in Implant Surgery in Anticoagulated Patients on Warfarin: a Randomized Clinical Study[NCT04846114] | 71 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Role of Topical Tranexamic Acid in Total Hip Arthroplasty[NCT01866943] | Phase 2 | 41 participants (Actual) | Interventional | 2011-11-30 | Terminated | ||
| Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement; A Prospective Triple-blinded Randomized Controlled Trial.[NCT01850394] | 152 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Evaluation of the Pharmacokinetic Profile of Tranexamic Acid, After Injection in a Knee Neo-articulation.[NCT02319915] | Early Phase 1 | 14 participants (Actual) | Interventional | 2015-02-18 | Completed | ||
| Tranexamic Acid in Knee Joint Surgery - a Randomised Controlled Trial[NCT02278263] | Phase 4 | 150 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Efficacy of Tranexamic Acid in Femoral Shaft Fractures Osteosynthesis; A Double Blind Randomized Controlled Trial[NCT04803591] | Phase 4 | 0 participants (Actual) | Interventional | 2021-08-01 | Withdrawn (stopped due to Not approved by Ethics Commettee) | ||
| Evaluation of the Use of Tranexamic Acid in Tibial Osteotomies: a Randomised Controlled Clinical Trial.[NCT04785651] | 84 participants (Anticipated) | Interventional | 2021-02-22 | Recruiting | |||
| Comparative Study of the Efficiency of Oral Tranexamic Tcid vs. Oral Tminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. A Prospective, Randomized, Double Blinded Controlled Clinical Trial.[NCT03365999] | Phase 2 | 92 participants (Actual) | Interventional | 2017-10-15 | Completed | ||
| Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid in Patients at High Risk for Blood Transfusion After Spine Surgery[NCT03849443] | Early Phase 1 | 604 participants (Anticipated) | Interventional | 2019-08-26 | Recruiting | ||
| The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery[NCT02684851] | Phase 3 | 87 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty[NCT01370460] | Phase 2 | 101 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Intravenous Tranexamic Acid to Reduce Blood Loss in Reverse Total Shoulder Arthroplasty[NCT02043132] | Phase 2/Phase 3 | 116 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Randomized Controlled Trial of Oral and Intravenous Tranexamic Acid in Lumbar Spine Surgery[NCT03037515] | Phase 4 | 120 participants (Anticipated) | Interventional | 2017-02-15 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Estimated Blood Loss defined as Pre Op Hgb mins the Post Op Day two Hgb. (NCT01866943)
Timeframe: Pre Op, Post Op Day 2
| Intervention | Hemoglobin (grams/deciliter) (Mean) |
|---|---|
| Baseline Population | 2.93 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 2 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 65.76 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 6 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 81.77 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: Preoperative
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 58.34 |
Measurement of the thigh at the half way point between the prominence of the greater trochanter and the lateral epicondyle of the femur. No data recorded at 2 weeks or 6 weeks for this study population. (NCT01866943)
Timeframe: Pre Op
| Intervention | centimeters (Mean) |
|---|---|
| Baseline Population | 52.99 |
(NCT01850394)
Timeframe: postoperative period (5 days after surgery)
| Intervention | participants (Number) |
|---|---|
| Control Group | 10 |
| TXA-250 Group | 6 |
| TXA-500 Group | 0 |
Total hemoglobin loos measured by difference between hemoglobin preoperatively and the fourth postoperative day (NCT01850394)
Timeframe: 5 days after surgery
| Intervention | g/dL (Mean) |
|---|---|
| Control Group | 2.9 |
| TXA-250 Group | 2.2 |
| TXA-500 Group | 2.2 |
"Knee function score was measured with 2 methods, and were evaluated preoperatively and then postoperatively at 3-month, 6-month, and 1-year period.~Knee Society Knee Score using for rating knee function measurement and subdivided into two parts; knee score and function score 1.1. Knee score : calculated from pain, presence of deformity, total range of flexion, alignment, and stability. Total score is 100 (0-100), more score means better.~1.2. Function score : calculated from patient's ability to walk and climb stairs. The score ranges from 0-100, more score means better.~Western Ontario and McMaster Universities Arthritis Index or WOMAC score : a widely used, standardized questionnaires for evaluating the condition of patients with knee osteoarthritis, including pain (score = 0-20), stiffness (0-8), and functional limitation (0-68). Total score ranges from 0-68, lower score means better." (NCT01850394)
Timeframe: 1 year after surgery
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Knee Society Knee score at 1 year | WOMAC score at 1 year | |
| Control Group | 148.9 | 15.5 |
| TXA-250 Group | 151.2 | 15.1 |
| TXA-500 Group | 150.9 | 14.5 |
"Postoperative complications were measured as an incidence of the following complications;~wound hematoma~surgical site infection~systemic infection~deep vein thrombosis~pulmonary embolism~knee stiffness requiring manipulation~medical complication such as myocardial infarction, congestive hear failure" (NCT01850394)
Timeframe: postoperative 1-year period
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Re-clamp incidence | Re-dressing incidence | Venous thromboembolic complication | Congestive heart failure | |
| Control Group | 6 | 3 | 4 | 0 |
| TXA-250 Group | 1 | 0 | 1 | 1 |
| TXA-500 Group | 0 | 0 | 2 | 0 |
"Drainage blood loss measured by accumulating total drainage volume postoperatively~Calculated total blood loss measured by using specific formula and difference between hematocrit preoperatively and the fourth postoperative day" (NCT01850394)
Timeframe: 5 days after surgery
| Intervention | ml (Median) | |
|---|---|---|
| Drainage blood loss | Calculated total blood loss | |
| Control Group | 546.9 | 329.2 |
| TXA-250 Group | 475.0 | 239.7 |
| TXA-500 Group | 430.2 | 217.2 |
"The loss of haemoglobin (Hb) was then estimated according to the formula:~Hb(loss) = Blood volume (BV) x (Hbi-Hbe) x 0.001+Hbt~where Hb (loss) (g) is the amount of Hb lost, Hbi (g/L) the Hb concentration before surgery, Hbe (g/L) is the Hbe concentration on the third day after surgery, and Hbt (g) is the total amount of allogeneic Hb transfused. A unit of banked blood is considered to contain a minimum of 40g Hb (Blood component data sheet, New Zealand Blood Services [NZBS]). All units of blood are processed and stored in a nationally standardised manner. The blood loss (ml) was related to the patient's preoperative Hb value (g/L):~Blood loss =1000 x Hb(loss) /Hbi" (NCT02278263)
Timeframe: Post operative day 3
| Intervention | mls (Mean) |
|---|---|
| Control | 1090 |
| Intraarticular | 716 |
| Systemic | 746 |
Day of surgery is counted as Day 0. (NCT02278263)
Timeframe: Average length of stay is expected to be 3 to 5 days
| Intervention | days (Median) |
|---|---|
| Control | 4 |
| Topical | 4 |
| Systemic | 4 |
"Those patients receiving blood products. Standardised protocol is as follows:~The criterion for transfusion of blood products will be a haemoglobin < 80g/L or a haemoglobin <100g/L in a patient with ischaemic heart disease or with significant symptomatology" (NCT02278263)
Timeframe: Participants will be followed for the duration of their hospital stay expected to be an average of 3-5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 2 |
| Topical | 1 |
| Systemic | 0 |
Intravenous fluid (excluding blood transfusion) given during and first 24 hours after surgery (NCT02278263)
Timeframe: Day 1
| Intervention | mls (Mean) |
|---|---|
| Control | 1765 |
| Topical | 1613 |
| Systemic | 1807 |
Rates of deep vein thrombosis (DVT) and pulmonary embolus (PE) in each group recorded as a percentage (NCT02278263)
Timeframe: Postoperatively within 30 days after surgery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| DVT | PE | |
| Control | 0 | 0 |
| Systemic | 0 | 1 |
| Topical | 0 | 2 |
Range of motion measured in degrees on postoperative days 1-3 (NCT02278263)
Timeframe: Days 1-3
| Intervention | degrees (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Control | 57 | 71 | 75 |
| Systemic | 58 | 72 | 78 |
| Topical | 65 | 75 | 82 |
Range of motion measured in degrees for postoperative days 1 to 3 (NCT02278263)
Timeframe: Days 1-3
| Intervention | degrees (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Control | 65 | 76 | 82 |
| Systemic | 68 | 80 | 87 |
| Topical | 74 | 81 | 87 |
Number of participant received allogenic blood transfusions. (NCT02684851)
Timeframe: post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 21 |
| Placebo | 13 |
To measure average estimate perioperative blood loss (NCT02684851)
Timeframe: perioperative
| Intervention | mL (Mean) |
|---|---|
| Tranexamic | 727.6 |
| Placebo | 560.1 |
Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo? (NCT02684851)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 1 |
| Placebo | 0 |
Average units packed red blood cells transfused among participants (NCT02684851)
Timeframe: perioperative
| Intervention | Units of packed red blood cells (Mean) |
|---|---|
| Tranexamic | 2.65 |
| Placebo | 2.36 |
Preoperative and lowest postoperative hemoglobin. Blood loss was calculated taking change in hemoglobin as described (units g/dL) and converting to blood loss (mL) according to the formulas included in the papers cited in this entry (Good 2003 Br J Anesthesia; Nadler 1962 Surgery, http://www.ncbi.nlm.nih.gov/pubmed/21936146). (NCT01370460)
Timeframe: participants will be followed for the duration of hospital stay, an expected average of 3 days
| Intervention | mL (Mean) |
|---|---|
| Placebo | 1293.1 |
| Tranexamic Acid | 940.2 |
Number of patients with symptomatic (tachycardia, hypotension, presyncope) anemia of < 8.0g/dL hemoglobin, or any hemoglobin <7.0 g/dL, precipitated transfusion. (NCT01370460)
Timeframe: participants will be followed for the duration of hospital stay, an expected average of 3 days
| Intervention | participants (Number) |
|---|---|
| Tranexamic Acid | 0 |
| Placebo | 4 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Deep venous thrombosis" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Hematoma" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Infection" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Myocardial infarction" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 1 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Pulmonary Embolism" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
Total Blood Loss as calculated according to method as described by Good et al. Total Blood Loss (mL) = 1000 X Hb(loss)/Hb(initial) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2
| Intervention | Total Blood Loss (mL) (Mean) |
|---|---|
| Tranexamic Acid | 1122.4 |
| Normal Saline | 1472 |
Total Drain Output as measured postoperatively 0-48 hours (NCT02043132)
Timeframe: 0-48 hours postoperatively
| Intervention | mL (Mean) |
|---|---|
| Tranexamic Acid | 221 |
| Normal Saline | 372 |
Total hemoglobin loss estimated using the formula for total blood volume described by Nadler et al Hb(loss) = blood volume (L) x [Hb(initial)(g/L) - Hb(final)(g/L)] + Hb(transfused) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2
| Intervention | g (Mean) |
|---|---|
| Tranexamic Acid | 154.6 |
| Normal Saline | 200.1 |
2 reviews available for tranexamic acid and Osteoarthritis, Knee
| Article | Year |
|---|---|
Tranexamic Acid in Total Knee Arthroplasty: Mixed Treatment Comparisons and Recursive Cumulative Meta-Analysis of Randomized, Controlled Trials and Cohort Studies.
Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Antifibrinolytic Agents; | 2018 |
Reduced blood loss after intra-articular tranexamic acid injection during total knee arthroplasty: a meta-analysis of the literature.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2014 |
42 trials available for tranexamic acid and Osteoarthritis, Knee
| Article | Year |
|---|---|
Use of tranexamic acid in medial open wedge high tibial osteotomy.
Topics: Hemoglobins; Humans; Osteoarthritis, Knee; Osteotomy; Pain, Postoperative; Postoperative Complicatio | 2022 |
Efficacy of intravenous tranexamic acid administration in medial opening-wedge distal tibial tuberosity osteotomy (MOWDTO) for varus knee osteoarthritis: a randomized control trial.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Osteoarthritis, | 2023 |
Monitoring of fibrinolytic system activity with plasminogen, D-dimers and FDP in primary total knee arthroplasty (TKA) after topical, intravenous or combined administration of tranexamic acid.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2020 |
Intra-articular tranexamic acid as an adjunct to intravenous tranexamic acid for simultaneous bilateral total knee arthroplasty: a randomized double-blind, placebo-controlled trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Chemotherapy, | 2019 |
Intravenous and subsequent long-term oral tranexamic acid in enhanced-recovery primary total knee arthroplasty without the application of a tourniquet: a randomized placebo-controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
The antifibrinolytic and anti-inflammatory effects of a high initial-dose tranexamic acid in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, | 2020 |
Topical co-delivery of platelet rich fibrin and tranexamic acid does not decrease blood loss in primary total knee arthroplasty compared to the standard of care: a prospective, randomized, controlled trial.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2021 |
Tranexamic acid in total knee replacement which protocol? which application form? A prospective randomised study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss | 2019 |
Are The Applications of Tranexamic Acid in Reverse Hybrid Total Knee Arthroplasty (TKA) The Same as Those in Fully Cemented TKA?: A Randomized Controlled Trial.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2021 |
Tranexamic Acid Reduces Occult Blood Loss, Blood Transfusion, and Improves Recovery of Knee Function after Total Knee Arthroplasty: A Comparative Study.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; F | 2018 |
A comparative analysis of the role of Tranexamic acid as an independent variable in reducing intraoperative blood loss in patients undergoing conventional total knee arthroplasty versus computer-assisted total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Hemogl | 2017 |
Comparison of intravenous and intra-articular tranexamic acid in reducing blood loss in primary total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2017 |
Comparing the efficacy of intravenous or intra-articular tranexamic acid in reducing blood loss in simultaneous bilateral knee replacement surgery without the use of tourniquet.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2018 |
Blood loss after intraarticular and intravenous tranexamic acid in total knee arthroplasty.
Topics: Adult; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; F | 2018 |
Multiple intravenous tranexamic acid doses in total knee arthroplasty without tourniquet: a randomized controlled study.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Hemoglobins; Humans; Os | 2019 |
Blood loss reduction: effect of different knee prosthesis designs and use of tranexamic acid-a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2019 |
Multi-route applications of tranexamic acid to reduce blood loss after total knee arthroplasty: a randomized controlled trial.
Topics: Age Factors; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; B | 2019 |
Post-operative blood loss in total knee arthroplasty: knee flexion versus pharmacological techniques.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Female; Humans; K | 2014 |
Knee flexion after total knee arthroplasty reduces blood loss.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Female; Humans; K | 2014 |
Reducing blood loss in simultaneous bilateral total knee arthroplasty: combined intravenous-intra-articular tranexamic acid administration. A prospective randomized controlled trial.
Topics: Aged; Analgesics; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Do | 2015 |
Single dose intravenous tranexamic acid as effective as continuous infusion in primary total knee arthroplasty: a randomised clinical trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Dose-Response Rel | 2015 |
Safety and efficacy of intra-articular tranexamic acid injection without drainage on blood loss in total knee arthroplasty: A randomized clinical trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2015 |
Intra-articular injection of tranexamic acid reduce blood loss in cemented total knee arthroplasty.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2015 |
[A PROSPECTIVE RANDOMIZED SELF-CONTROLLED STUDY ON EFFECT OF TRANEXAMIC ACID IN REDUCING BLOOD LOSS IN TOTAL KNEE ARTHROPLASTY].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2015 |
Intravenous versus intra-articular tranexamic acid in total knee arthroplasty: A double-blinded randomised controlled noninferiority trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
Topical vs Intravenous Tranexamic Acid in Reducing Blood Loss After Bilateral Total Knee Arthroplasty: A Prospective Study.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2016 |
Effect of Topical and Intravenously Applied Tranexamic Acid Compared to Control Group on Bleeding in Primary Unilateral Total Knee Arthroplasty.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2017 |
Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2016 |
Intravenous vs Topical Tranexamic Acid in Total Knee Arthroplasty Without Tourniquet Application: A Randomized Controlled Study.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2016 |
Peri-articular tranexamic acid injection in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood T | 2016 |
Peri-articular tranexamic acid injection in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood T | 2016 |
Peri-articular tranexamic acid injection in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood T | 2016 |
Peri-articular tranexamic acid injection in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood T | 2016 |
Topical tranexamic acid versus autotransfusion after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion, Autologous; Cost- | 2016 |
Combined Administration of IV and Topical Tranexamic Acid is Not Superior to Either Individually in Primary Navigated TKA.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2017 |
Optimizing effectivity of tranexamic acid in bilateral knee arthroplasty - A prospective randomized controlled study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty.
Topics: Administration, Oral; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacem | 2017 |
Clamping drainage is unnecessary after minimally invasive total knee arthroplasty in patients with tranexamic acid: A randomized, controlled trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Constriction; | 2017 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Edema; Female; | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial.
Topics: Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Bl | 2011 |
Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Double-Blind Meth | 2012 |
Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Double-Blind Meth | 2012 |
Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Double-Blind Meth | 2012 |
Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Double-Blind Meth | 2012 |
Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Double-Blind Meth | 2012 |
Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Double-Blind Meth | 2012 |
Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Double-Blind Meth | 2012 |
Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Double-Blind Meth | 2012 |
Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Double-Blind Meth | 2012 |
Less blood loss under concomitant administration of tranexamic acid and indirect factor Xa inhibitor following total knee arthroplasty: a prospective randomized controlled trial.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical | 2013 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blind Meth | 2003 |
[Clinical comparative studies on effect of tranexamic acid on blood loss associated with total knee arthroplasty].
Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Bl | 2007 |
28 other studies available for tranexamic acid and Osteoarthritis, Knee
| Article | Year |
|---|---|
Natural course of hemoglobin level after total knee arthroplasty and the benefit of tranexamic acid injection in the joint.
Topics: Aged; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Hemoglobins; Humans; Injections | 2021 |
Impact of tourniquet on short-term outcomes in opening wedge high tibial osteotomy with modern tranexamic acid protocols: a retrospective cohort study.
Topics: Humans; Osteoarthritis, Knee; Osteotomy; Retrospective Studies; Tibia; Tourniquets; Tranexamic Acid | 2021 |
Comparison of intra-articular administration of adenosine, lidocaine and magnesium solution and tranexamic acid for alleviating postoperative inflammation and joint fibrosis in an experimental model of knee arthroplasty.
Topics: Adenosine; Administration, Intravenous; Animals; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2021 |
The effect of topical tranexamic acid on functional outcomes and quality of life in patients undergoing unicompartmental knee arthroplasty.
Topics: Administration, Topical; Arthroplasty, Replacement, Knee; Humans; Knee Joint; Osteoarthritis, Knee; | 2023 |
The effect of topical tranexamic acid on functional outcomes and quality of life in patients undergoing unicompartmental knee arthroplasty.
Topics: Administration, Topical; Arthroplasty, Replacement, Knee; Humans; Knee Joint; Osteoarthritis, Knee; | 2023 |
The effect of topical tranexamic acid on functional outcomes and quality of life in patients undergoing unicompartmental knee arthroplasty.
Topics: Administration, Topical; Arthroplasty, Replacement, Knee; Humans; Knee Joint; Osteoarthritis, Knee; | 2023 |
The effect of topical tranexamic acid on functional outcomes and quality of life in patients undergoing unicompartmental knee arthroplasty.
Topics: Administration, Topical; Arthroplasty, Replacement, Knee; Humans; Knee Joint; Osteoarthritis, Knee; | 2023 |
Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia.
Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthralgia; Arthroplasty, Replacement, | 2019 |
Intravenous Combined with Topical Tranexamic Acid Administration Has No Additional Benefits Compared with Intravenous Administration Alone in High Tibial Osteotomy: A Retrospective Case-Control Study.
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Case-Control St | 2020 |
Higher doses of topical tranexamic acid safely improves immediate functional outcomes and reduces transfusion requirement in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2020 |
Does the correction angle affect hidden blood loss in HTO?
Topics: Aged; Blood Loss, Surgical; Female; Humans; Knee Joint; Male; Middle Aged; Osteoarthritis, Knee; Ost | 2020 |
Tranexamic acid is effective for blood management in open-wedge high tibial osteotomy.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Case-Control Studies | 2018 |
Early morbidity and mortality after single-stage bilateral total knee replacement.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss | 2018 |
Blood loss of total knee arthroplasty in osteoarthritis: an analysis of influential factors.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2018 |
The efficacy and safety of tranexamic acid for reducing blood loss following simultaneous bilateral total knee arthroplasty: a multicenter retrospective study.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2019 |
Intraarticular use of tranexamic acid reduces blood loss and transfusion rate after primary total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2019 |
Inadequate methodology renders results on the use of tranexamic acid inconclusive.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Humans; Male | 2013 |
Reply to Letter to the Editor: Inadequate methodology renders results on the use of tranexamic acid inconclusive.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Humans; Male | 2013 |
A prospective study on role of tranexamic acid in reducing postoperative blood loss in total knee arthroplasty and its effect on coagulation profile.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Coagulation; Case-Control Studies; D | 2014 |
Can tranexamic acid and hydrogen peroxide reduce blood loss in cemented total knee arthroplasty?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2014 |
Intra-articular injection of tranexamic acid to reduce blood loss after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Dose-Response Rel | 2014 |
Letter to the Editor: Intra-articular injection of tranexamic acid to reduce blood loss after total knee arthroplasty.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Female; Humans; Male; Osteoarthritis, Knee | 2014 |
[Blood loss during total knee-joint replacement: a combination of anticoagulant and hemostatic techniques].
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Etha | 2014 |
Authors' reply.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Female; Humans; Male; Osteoarthritis, Knee | 2014 |
Low-volume formulation of intra-articular tranexamic acid, 25-ml tranexamic acid (2.5 g) plus 20-ml saline, is effective in decreasing blood transfusion rate in primary total knee replacement even without preoperative haemoglobin optimization.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2016 |
The Efficacy Comparison of Tranexamic Acid for Reducing Blood Loss in Total Knee Arthroplasty at Different Dosage Time.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2017 |
Topical Tranexamic Acid in Total Knee Arthroplasty Patients with Increased Thromboembolic Risk.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2017 |
A comparative, retrospective study of peri-articular and intra-articular injection of tranexamic acid for the management of postoperative blood loss after total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Transfusion; Drainage; Female; | 2016 |
Use of tranexamic acid is a cost effective method in preventing blood loss during and after total knee replacement.
Topics: Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Blood Loss, Surgica | 2011 |
Tranexamic acid reduces blood loss and financial cost in primary total hip and knee replacement surgery.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplast | 2012 |
Repeat-dose intravenous tranexamic acid further decreases blood loss in total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2013 |